Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:49 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 16,128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Phase 2 Interventional

Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy

NCT00067314
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Edotecarin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
7
States / cities
Manhasset, New York • New York, New York • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Nov 3, 2026, 4:49 PM EST
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT01803321
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
rilonacept (IL-1 Trap), Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
4 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Nov 3, 2026, 4:49 PM EST
Recruiting Phase 1Phase 2 Interventional

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NCT05490472
View directory record Official record
Conditions
Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Interventions
JAB-2485 (Aurora A inhibitor)
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 3, 2026, 4:49 PM EST
Completed No phase listed Observational Accepts healthy volunteers

CARE: Cancer Risk Perception and Women of Color

NCT06036875
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 3, 2026, 4:49 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Use of Shade in U.S. and Australian City Parks

NCT02971709
View directory record Official record
Conditions
Skin Cancer
Interventions
Shade Sail
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Nov 3, 2026, 4:49 PM EST
Completed No phase listed Observational

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

NCT01276899
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsies, Needle core biopsies of metastatic lesion
Procedure
Lead sponsor
Jewish General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Nov 3, 2026, 4:49 PM EST
Active, not recruiting Phase 3 Interventional

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

NCT02262832
View directory record Official record
Conditions
Lipodystrophy, Diabetes, Hyperlipidemia
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 98 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 3, 2026, 4:49 PM EST
Completed Not applicable Interventional

Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer

NCT00627614
View directory record Official record
Conditions
Breast Cancer
Interventions
breast imaging study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Nov 3, 2026, 4:49 PM EST
Completed Phase 1 Interventional

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

NCT00716014
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
TD101, Normal saline (placebo)
Drug
Lead sponsor
Pachyonychia Congenita Project
Other
Eligibility
10 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Nov 3, 2026, 4:49 PM EST
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 3, 2026, 4:49 PM EST
Recruiting Phase 2 Interventional

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BI 3000202, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Beverly Hills, California • La Palma, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 4:49 PM EST
Not listed Not applicable Interventional

The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient

NCT01521000
View directory record Official record
Conditions
Breast Cancer
Interventions
Garment Sleeve
Device
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Nov 3, 2026, 4:49 PM EST
Completed Phase 1Phase 2 Interventional Results available

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

NCT01325207
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Nov 3, 2026, 4:49 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Sun Safety Skills for Elementary School Students

NCT03752736
View directory record Official record
Conditions
Sunburn, Skin Cancer Prevention
Interventions
"I wear sunscreen everyday" song-based video
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 7 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cupertino, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Nov 3, 2026, 4:49 PM EST
Active, not recruiting Phase 3 Interventional

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

NCT06768671
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
12 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
North Little Rock, Arkansas • Stanford, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 3, 2026, 4:49 PM EST
Completed Not applicable Interventional

A Couples Approach to Enhance Breast Cancer Survivorship

NCT00665899
View directory record Official record
Conditions
Early-Stage Breast Cancer
Interventions
Cancer-Focused Relationship Enhancement, Couple's Cancer Education
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Nov 3, 2026, 4:49 PM EST
Completed Phase 1 Interventional

131-I-TM-601 Study in Adults With Solid Tumors

NCT00379132
View directory record Official record
Conditions
Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
Interventions
131-I-TM-601 (chlorotoxin)
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Nov 3, 2026, 4:49 PM EST
Completed No phase listed Observational

A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

NCT00515398
View directory record Official record
Conditions
Pompe Disease, Glycogen Storage Disease Type II
Interventions
Observation
Other
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Gainesville, Florida • St Louis, Missouri • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Nov 3, 2026, 4:49 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging

NCT04137263
View directory record Official record
Conditions
Melasma
Interventions
DOSE formulation
Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 3, 2026, 4:49 PM EST
Recruiting Phase 1 Interventional

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04897321
View directory record Official record
Conditions
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Interventions
Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 3, 2026, 4:49 PM EST
Active, not recruiting Phase 1 Interventional

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121
View directory record Official record
Conditions
Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Interventions
ADRX-0706
Drug
Lead sponsor
Adcentrx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • St. Petersburg, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Nov 3, 2026, 4:49 PM EST
Terminated Phase 2 Interventional Results available

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

NCT03791060
View directory record Official record
Conditions
Necrobiosis Lipoidica Diabeticorum
Interventions
Secukinumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 110 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Nov 3, 2026, 4:49 PM EST
Withdrawn Phase 1 Interventional

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

NCT05600582
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
CodaLytic
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Nov 3, 2026, 4:49 PM EST
Active, not recruiting Phase 1 Interventional

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579
View directory record Official record
Conditions
Breast Cancer
Interventions
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 4:49 PM EST